Sialidase NEU3 Contributes to the Invasiveness of Bladder Cancer

• Published in: Biomedicines Vol. 12; no. 1; p. 192
• Main Authors: Tatsuta, Takeo, Ito, Jun, Yamamoto, Koji, Sugawara, Shigeki, Hosono, Masahiro, Sato, Makoto, Miyagi, Taeko
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01-01-2024
• Subjects: 1-Phosphatidylinositol 3-kinase; Acids; Adjuvant treatment; Analysis; Bladder cancer; Cancer; Cells; Chemotherapy; Cisplatin; Diagnostic reagents industry; Ethylenediaminetetraacetic acid; Health aspects; invasion; Invasiveness; Malignancy; Membranes; Metastasis; Motility; Organic acids; Pharmaceuticals; Proteins; Response rates; sialidase; siRNA; Therapeutic targets; Tumor cell lines; United States; Japan; United States > US; sialidase; invasion; bladder cancer
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines12010192

Bladder cancer is the 10th most commonly diagnosed cancer worldwide. The current standard treatment for advanced bladder cancer is neoadjuvant cisplatin (NAC)-based chemotherapy followed by cystectomy. However, the response rate to chemotherapy is only 50%, owing to cisplatin resistance, and there is a need for novel therapies. Because the invasiveness of bladder cancer greatly influences patient prognosis, a mechanistic analysis of the invasive function can lead to therapeutic targets. Sialidases, which remove sialic acid residues from the nonreducing ends of sugar chains and catalyze the initial reaction in the degradation of sugar chains, are predicted to be involved in cell invasion and motility. However, the involvement of sialidases in bladder cancer, especially their relationship with the invasive ability, remains unclear. Here, using patient tissues and multiple bladder cancer cell lines, we show that the sialidase
is highly expressed in bladder cancer. Analysis of NEU3's function using its siRNA-mediated knockdown revealed that NEU3 contributes to bladder cancer invasiveness. Mechanistic analysis showed that NEU3 activates ERK and PI3K signaling. Our results show that NEU3 is involved in the malignancy of bladder cancer, and its suppression may lead to novel treatments for bladder cancer.